-
Je něco špatně v tomto záznamu ?
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
L. Burgos, LE. Tamariz-Amador, N. Puig, MT. Cedena, C. Guerrero, T. Jelínek, S. Johnson, P. Milani, L. Cordon, JJ. Perez, M. Lasa, R. Termini, A. Oriol, MT. Hernandez, L. Palomera, R. Martinez-Martinez, J. de la Rubia, F. de Arriba, R. Rios, ME....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2004 do Před 1 rokem
Open Access Digital Library
od 1999-01-01
PubMed
36930848
DOI
10.1200/jco.22.01916
Knihovny.cz E-zdroje
- MeSH
- fenotyp MeSH
- klinická relevance MeSH
- lidé MeSH
- mnohočetný myelom * diagnóza MeSH
- monoklonální gamapatie nejasného významu * diagnóza terapie MeSH
- paraproteinemie * diagnóza terapie MeSH
- primární amyloidóza * MeSH
- progrese nemoci MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
PURPOSE: The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated. PATIENTS AND METHODS: An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis. RESULTS: Patients with smoldering MM with MGUS-like phenotype showed significantly lower rates of disease progression (4.5% and 0% at 2 years in two independent series). There were no statistically significant differences in time to progression between treatment versus observation in these patients. In active newly diagnosed MM, MGUS-like phenotype retained independent prognostic value in multivariate analyses of progression-free survival (PFS; hazard ratio [HR], 0.49; P = .001) and overall survival (OS; HR, 0.56; P = .039), together with International Staging System, lactate dehydrogenase, cytogenetic risk, transplant eligibility, and complete remission status. Transplant-eligible patients with active MM with MGUS-like phenotype showed PFS and OS rates at 5 years of 79% and 96%, respectively. In this subgroup, there were no differences in PFS and OS according to complete remission and measurable residual disease status. Application of the algorithm in two independent series of patients with AL predicted for different survival. CONCLUSION: We developed an open-access algorithm for the identification of MGUS-like patients with distinct clinical outcomes. This phenotypic classification could become part of the diagnostic workup of MM and AL amyloidosis.
4th Department of Medicine Haematology Charles University Hospital Hradec Králové Czech Republic
Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic
Department of Hematology University Hospital Vall d'Hebron Barcelona Spain
Hematology Department Hospital Costa del Sol Marbella Marbella Spain
Hematology Department University Hospital La Fe Valencia Spain
Hospital Clínico San Carlos Madrid Spain
Hospital Clínico Universitario Lozano Blesa Zaragoza Spain
Hospital Clínico Universitario Virgen de la Arrixaca IMIB Arrixaca University of Murcia Murcia Spain
Hospital de Cabueñes Gijón Spain
Hospital Morales Meseguer IMIB Arrixaca Universidad de Murcia Murcia Spain
Hospital Universitario de Canarias Santa Cruz de Tenerife Spain
Hospital Universitario de Salamanca CIBERONC Salamanca Spain
Hospital Universitario La Fe Valencia Spain
Hospital Universitario Puerta de Hierro Hospital Madrid Spain
Hospital Universitario Son Espases Palma Spain
Tom Baker Cancer Center Department of Hematology University of Calgary Calgary AB Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011264
- 003
- CZ-PrNML
- 005
- 20230801132920.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1200/JCO.22.01916 $2 doi
- 035 __
- $a (PubMed)36930848
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Burgos, Leire $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain
- 245 10
- $a Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies / $c L. Burgos, LE. Tamariz-Amador, N. Puig, MT. Cedena, C. Guerrero, T. Jelínek, S. Johnson, P. Milani, L. Cordon, JJ. Perez, M. Lasa, R. Termini, A. Oriol, MT. Hernandez, L. Palomera, R. Martinez-Martinez, J. de la Rubia, F. de Arriba, R. Rios, ME. Gonzalez, M. Gironella, V. Cabañas, M. Casanova, I. Krsnik, A. Perez-Montaña, V. González-Calle, P. Rodriguez-Otero, V. Maisnar, R. Hajek, F. Van Rhee, V. Jimenez-Zepeda, G. Palladini, G. Merlini, A. Orfao, J. de la Cruz, J. Martinez-Lopez, JJ. Lahuerta, L. Rosiñol, J. Blade, MV. Mateos, JF. San-Miguel, B. Paiva, PETHEMA/GEM Cooperative Group
- 520 9_
- $a PURPOSE: The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated. PATIENTS AND METHODS: An algorithm to identify patients having MGUS-like phenotype was developed on the basis of the percentages of total bone marrow (BM) plasma cells (PC) and of clonal PC within the BM PC compartment, determined at diagnosis using flow cytometry in 548 patients with MGUS and 2,011 patients with active MM. The clinical significance of the algorithm was tested and validated in 488 patients with smoldering MM, 3,870 patients with active MM and 211 patients with AL amyloidosis. RESULTS: Patients with smoldering MM with MGUS-like phenotype showed significantly lower rates of disease progression (4.5% and 0% at 2 years in two independent series). There were no statistically significant differences in time to progression between treatment versus observation in these patients. In active newly diagnosed MM, MGUS-like phenotype retained independent prognostic value in multivariate analyses of progression-free survival (PFS; hazard ratio [HR], 0.49; P = .001) and overall survival (OS; HR, 0.56; P = .039), together with International Staging System, lactate dehydrogenase, cytogenetic risk, transplant eligibility, and complete remission status. Transplant-eligible patients with active MM with MGUS-like phenotype showed PFS and OS rates at 5 years of 79% and 96%, respectively. In this subgroup, there were no differences in PFS and OS according to complete remission and measurable residual disease status. Application of the algorithm in two independent series of patients with AL predicted for different survival. CONCLUSION: We developed an open-access algorithm for the identification of MGUS-like patients with distinct clinical outcomes. This phenotypic classification could become part of the diagnostic workup of MM and AL amyloidosis.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a monoklonální gamapatie nejasného významu $x diagnóza $x terapie $7 D008998
- 650 _2
- $a klinická relevance $7 D000092522
- 650 12
- $a primární amyloidóza $7 D000075363
- 650 _2
- $a progrese nemoci $7 D018450
- 650 12
- $a paraproteinemie $x diagnóza $x terapie $7 D010265
- 650 12
- $a mnohočetný myelom $x diagnóza $7 D009101
- 650 _2
- $a fenotyp $7 D010641
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tamariz-Amador, Luis-Esteban $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/0000000240880992
- 700 1_
- $a Puig, Noemi $u Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain $1 https://orcid.org/0000000175353861
- 700 1_
- $a Cedena, Maria-Teresa $u Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain $1 https://orcid.org/0000000158513720
- 700 1_
- $a Guerrero, Camila $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/0000000313955140
- 700 1_
- $a Jelínek, Tomas $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000254679253
- 700 1_
- $a Johnson, Sarah $u Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
- 700 1_
- $a Milani, Paolo $u Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy $1 https://orcid.org/0000000222689422
- 700 1_
- $a Cordon, Lourdes $u Hospital Universitario La Fe, Valencia, Spain $1 https://orcid.org/0000000288083423
- 700 1_
- $a Perez, Jose J $u Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
- 700 1_
- $a Lasa, Marta $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/000000022981162X
- 700 1_
- $a Termini, Rosalinda $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/0000000172638415
- 700 1_
- $a Oriol, Albert $u Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain $1 https://orcid.org/0000000168042221
- 700 1_
- $a Hernandez, Miguel-Teodoro $u Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain $1 https://orcid.org/0000000265767881
- 700 1_
- $a Palomera, Luis $u Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain $1 https://orcid.org/0000000303597191
- 700 1_
- $a Martinez-Martinez, Rafael $u Hospital Clínico San Carlos, Madrid, Spain
- 700 1_
- $a de la Rubia, Javier $u Hematology Department, University Hospital La Fe, Valencia, Spain $1 https://orcid.org/000000028354768X
- 700 1_
- $a de Arriba, Felipe $u Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
- 700 1_
- $a Rios, Rafael $u Hospital Universitario Puerta de Hierro, Hospital, Madrid, Spain $1 https://orcid.org/0000000181931402
- 700 1_
- $a Gonzalez, Maria-Esther $u Hospital de Cabueñes, Gijón, Spain $1 https://orcid.org/0000000242380377
- 700 1_
- $a Gironella, Mercedes $u Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain $1 https://orcid.org/0000000281068909
- 700 1_
- $a Cabañas, Valentin $u Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, Spain $1 https://orcid.org/0000000262482549
- 700 1_
- $a Casanova, Maria $u Hematology Department, Hospital Costa del Sol Marbella, Marbella, Spain
- 700 1_
- $a Krsnik, Isabel $u Hospital Universitario Puerta de Hierro, Hospital, Madrid, Spain $1 https://orcid.org/0000000229125072
- 700 1_
- $a Perez-Montaña, Albert $u Hospital Universitario Son Espases, Palma, Spain $1 https://orcid.org/0000000327080090
- 700 1_
- $a González-Calle, Verónica $u Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain $1 https://orcid.org/0000000254936707
- 700 1_
- $a Rodriguez-Otero, Paula $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/0000000152367785
- 700 1_
- $a Maisnar, Vladimir $u 4th Department of Medicine-Haematology, Charles University Hospital, Hradec Králové, Czech Republic
- 700 1_
- $a Hajek, Roman $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
- 700 1_
- $a Van Rhee, Fritz $u Myeloma Center/Division of Hematology Oncology/Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR $1 https://orcid.org/0000000199591282
- 700 1_
- $a Jimenez-Zepeda, Victor $u Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Palladini, Giovanni $u Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy $1 https://orcid.org/0000000159945138
- 700 1_
- $a Merlini, Giampaolo $u Department of Molecular Medicine, University of Pavia and Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy $1 https://orcid.org/0000000176803254
- 700 1_
- $a Orfao, Alberto $u Hospital Universitario de Salamanca (HUSAL), IBSAL, Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, University of Salamanca, CIBERONC, Salamanca, Spain $1 https://orcid.org/0000000200077230
- 700 1_
- $a de la Cruz, Javier $u Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain
- 700 1_
- $a Martinez-Lopez, Joaquin $u Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain $1 https://orcid.org/0000000179080063
- 700 1_
- $a Lahuerta, Juan-Jose $u Hematology Department, Hospital Universitario 12 de Octubre, CIBERONC, Instituto de Investigación IMAS12, Madrid, Spain $1 https://orcid.org/0000000233939570
- 700 1_
- $a Rosiñol, Laura $u Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain $1 https://orcid.org/0000000225349239
- 700 1_
- $a Blade, Joan $u Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
- 700 1_
- $a Mateos, Maria-Victoria $u Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain $1 https://orcid.org/0000000323901218
- 700 1_
- $a San-Miguel, Jesus F $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/0000000291834857 $7 xx0060803
- 700 1_
- $a Paiva, Bruno $u Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Universidad de Navarra, CCUN, IDISNA, CIBERONC, Pamplona, Spain $1 https://orcid.org/0000000319773815
- 710 2_
- $a PETHEMA/GEM Cooperative Group
- 773 0_
- $w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 16 (2023), s. 3019-3031
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36930848 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132917 $b ABA008
- 999 __
- $a ok $b bmc $g 1963578 $s 1197529
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 41 $c 16 $d 3019-3031 $e 20230317 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
- LZP __
- $a Pubmed-20230718
